However, although somatostatin analogs proved to be effective treatments in aggressive pulmonary carcinoids [98], somatostatin receptor expression has no role in predicting the response to somatostatin analogs in thoracic well-differentiated neuroendocrine neoplasms. The gene discussed is SST; the disease is neuroendocrine neoplasm.